For decades, Alzheimer’s research has been tied to hospitals and specialist centres, largely because confirming the disease requires brain scans, spinal fluid tests or carefully handled blood samples.
That dependence has narrowed who can take part in studies and slowed efforts to reach broader populations.
A new international study suggests a different path. Researchers have demonstrated that Alzheimer’s-related biomarkers can be measured using a simple finger-prick blood sample, dried on a card and sent by post.
The work was led by Banner Health in the United States with contributions from multiple European institutions, including the University of Exeter, and has been published in Nature Medicine.
Also read: AI concluded that X-rays of knees could reveal whether you drank beer
What the study shows
The research involved 337 participants across seven European medical centres. Scientists tested whether dried blood spots collected from a fingertip could reliably detect proteins linked to Alzheimer’s disease and brain damage.
Results showed strong agreement between finger-prick samples and standard blood tests. Participants were also able to collect samples themselves without clinical supervision, following written instructions.
This suggests large-scale studies could be conducted without requiring people to visit specialised facilities.
While the approach is not ready for clinical diagnosis, it removes major logistical barriers that have historically limited Alzheimer’s research to well-resourced settings.
Also read: A safer method for weight loss examined in a new study
Why p-tau217 matters
A central focus of the study was the biomarker p-tau217. Compared with older blood markers, p-tau217 is considered more closely tied to the specific brain changes seen in Alzheimer’s disease and better at distinguishing it from other dementias.
Researchers found that p-tau217 measured from finger-prick samples closely matched results from conventional blood draws and aligned well with changes detected in spinal fluid. Other markers, including GFAP and NfL, also performed reliably.
The findings point toward a future where Alzheimer’s research can reach more diverse populations, support larger studies and potentially enable earlier identification of people at risk, long before symptoms appear.
Sources: Nature Medicine and News Medical
Also read: What Donald Trump’s daily eating habits look like
Also read: This is what happens in your family when alcohol is removed from everyday life for a month